DECISION TO LIST AND PUBLICATION OF PROSPECTUS
STENOCARE A/S (“STENOCARE”) today announces that it has been approved by Nasdaq Copenhagen A/S for admission on Nasdaq First North Growth Market Denmark with the first day of trading on that market expected to be 18 May 2020. In connection with this listing STENOCARE has prepared a Prospectus which has been approved by the Danish Financial Supervisory Authority. The Prospectus includes a fundraise to fuel international acceleration.
A copy of the prospectus and the accompanying Press Release “RAISING UP TO 45 MILLION DKK FOR INTERNATIONAL ACCELERATION”, describing the offer, the motives, goals etc. has been attached.
STENOCARE shares are currently listed on Spotlight Stock Market and STENOCARE will de-list from that market with the last day of trading, expected to be 15 May 2020.
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
“I would like to thank Spotlight for getting us off to a good start as a public company. Now, the time has come to move on. With today’s announcement we start the journey towards European leadership in our industry and along with that, towards a future move to Nordic SmallCap on Nasdaq. With our listing on Nasdaq First North Growth Market Denmark and the capital raise for acceleration that we announce today, we take the first big steps in this direction”.
Important practical information:
Same share: The share will be unchanged and carry the same stock ticker: [STENO] and ISIN code is unchanged: DK0061078425 in VP Securities.
Certified Advisor: Keswick Global is appointed as Certified Adviser.
More information: More information about the upcoming Rights Issue as well as the Prospectus can be found and may be downloaded from the STENOCARE website at https://stenocare.com/investor-relations/share-issue-2020/.
Danish Law: STENOCARE is a Danish company operating under Danish law, including the Danish Companies Act (Selskabsloven) and the Capital Markets Act (Kapitalmarkedsloven). Once the Company’s shares cease to be traded on Spotlight Stock Market, the Company will no longer be subject Swedish securities legislation.
Attachments:
- Prospectus dated 11 May 2020
- Press Release: RAISING UP TO 45 MILLION DKK FOR INTERNATIONAL ACCELERATION
This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on May 11th, 2020.
For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO
Phone: +45 31770060
E-mail: presse@stenocare.com
Certified Adviser
STENOCARE’s Certified Adviser will be Keswick Global AG, Reg. FN 332389 h, Hoffingergasse 16/1/6, 1120 Vienna, Austria, telephone number +43 (1) 533 88 90 0. E-mail: info@keswickglobal.com
About STENOCARE A/S
STENOCARE A/S was founded in 2017 with the purpose of being an active participant in the Danish medical cannabis pilot program. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. The company offers medical cannabis oil that complies with the strict Danish regulatory requirements. STENOCARE is building a state-of-the-art production facility for the cultivation and production of medical cannabis at the company’s premises in Jutland, Denmark.